X. Tu

发表

Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A)

Yongping Song, D. Liu, Jifeng Yu, 2022, Molecules.

Single-cell data-driven mathematical model reveals possible molecular mechanisms of embryonic stem-cell differentiation.

Xiufen Zou, Wei Zhang, Qin Zhang, 2019, Mathematical biosciences and engineering : MBE.

Clinical evaluation of natalizumab for formulary consideration

F. Shaya, T. Dowling, S. Montenegro, 2010, Expert opinion on biological therapy.

RSPO2 suppresses colorectal cancer metastasis by counteracting the Wnt5a/Fzd7-driven noncanonical Wnt pathway.

O. Wang, Xincheng Lu, Tianke Chen, 2017, Cancer letters.

Abstract 545: Preclinical development of a bispecific antibody-trap selectively targeting CD47 and CD20 for the treatment of B cell lineage cancer

Liang Peng, Chunmei Yang, Wenzhi Tian, 2019, Clinical Research (Excluding Clinical Trials).

GTI-2501. Lorus Therapeutics.

X. Tu, G. Tu, 2001, Current opinion in investigational drugs.

SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the “don’t eat me” signal and activating the “eat me” signal

Yongping Song, D. Liu, Jifeng Yu, 2022, Journal of Hematology & Oncology.

The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling

D. Liu, Wenzhi Tian, Song Li, 2023, Frontiers in oncology.

IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy

D. Liu, Jifeng Yu, Wenzhi Tian, 2023, Antibody therapeutics.

Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38

D. Liu, Wenzhi Tian, Song Li, 2024, Frontiers in Immunology.